Navigation Links
Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
Date:11/15/2010

COLUMBIA, Md., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company, today announced financial results for the third quarter and nine months ended September 30, 2010 and addressed the progress of its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.  ThermoDox® is currently being evaluated under a Special Protocol Assessment with the FDA in a 600 patient pivotal Phase III trial (the HEAT study) in patients with non-resectable primary liver cancer and in a Phase I/II trial for patients with recurrent chest wall breast cancer.   The HEAT study has been designated as a Priority Trial for liver cancer by the National Institutes of Health.

"We are approaching 80% completion of patient enrollment into our Phase III primary liver cancer HEAT study of ThermoDox®.  Together with our Special Protocol Assessment for the HEAT study, Celsion received Fast Track Designation from the FDA providing us with the opportunity to file our New Drug Application on a rolling basis.  We now have an efficient clinical and regulatory pathway for commercialization of ThermoDox®," said Michael Tardugno, Celsion's President and Chief Executive Officer.Financial Results For the third quarter ended September 30, 2010, Celsion reported a net loss from operations of $5.2 million compared to a net loss from operations of $4.7 million for the same period of 2009.  For the first nine months of 2010, net cash used in operations was $10.6 million.  Celsion reported a net loss from operations of $14.2 million for the first nine months of 2010 compared to a net loss from operations of $13.2 million for the same period of 2009.  In the third quart
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
4. Par Pharmaceutical Reports Second Quarter 2008 Results
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. Pharmos Corporation Reports 2008 Second Quarter Results
7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. BMP Sunstone Reports Second Quarter 2008 Financial Results
10. ULURU Inc. Reports Second Quarter 2008 Financial Results
11. Immtech Reports Fiscal First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Israel , Dec. 15, 2014 /PRNewswire/ ... a leading developer of adult stem cell technologies for ... Therapeutics Ltd. was awarded a grant of approximately $1.1 ... the Chief Scientist (OCS).  This is the eighth year ... from the Office of the Chief Scientist, which is ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin Unite ... that they have joined forces to support Canadian entrepreneurs tackling ... Virgin Group Founder was at the MaRS Centre to announce ... national impact venture fund. This fund has $1 million in ... Vancouver -based Mindset Social Innovation Foundation, founded by ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... , Rep. Patrick Kennedy Joins ... U.S. Leadership in Research and Development while Boosting Rhode ... PROVIDENCE, R.I., Dec. 14 Several of Rhode Island,s ... today at Brown University,s Medical Research Facility to discuss ...
... , WALTHAM, Mass., Dec. 14 Decision Resources, one of the ... finds that, owing to the launches of several new agents, the ... million in 2008 to $6.1 billion in 2018 in the United ... The new Pharmacor report entitled Atrial Fibrillation finds that ...
... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ...
Cached Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... shape may predict the survival of corals around the world ... come, according to a new model that relies on engineering ... climate change, as well as future tsunamis, will have major ... week in the international scientific journal Nature. Shape and size ...
... enzyme found naturally in the brain snips apart the protein ... of the hallmarks of Alzheimer's disease (AD), researchers have found. ... called Cathepsin B (CatB), is a key part of a ... Also, they said their findings suggest that drugs to enhance ...
... dramatic increase in testicular cancer, now the most ... the focus of a five-year, $5.5 million National ... researcher Tongzhang Zheng. , Testicular cancer is increasing ... important information on possible environmental, genetic and other ...
Cached Biology News:Coral reefs are increasingly vulnerable to angry oceans 2Coral reefs are increasingly vulnerable to angry oceans 3Enzyme shreds Alzheimer's protein 2
... polyacrylamide gel electrophoresis (2D-PAGE) with biological mass ... technology platform for proteomic analysis. 2D-PAGE gels ... limited only in the dynamic range and ... Quantitative image based analysis of separated proteins ...
... supply is a highly compact, extremely reliable and ... knob and one hi-lo range switch control the ... from 20 to 250 volts. One two-position switch ... voltage to output current. For maximum safety, the ...
... a compact, lightweight, high current power supply capable ... milliamps. It is an excellent choice for PAGE, ... is also ideal for all types of electroblotting ... to automatically end a run and wil automatically ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: